Cargando…

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world and its incidence is increasing in many countries. In recent years, with the deepening understanding of the immune and pathological mechanisms of HCC, immunotherapy based on the regulation of tumor immune microenvi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hao-Tian, Jiang, Meng-Jie, Deng, Zhu-Jian, Li, Le, Huang, Jian-Li, Liu, Zhen-Xiu, Li, Le-Qun, Zhong, Jian-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570111/ https://www.ncbi.nlm.nih.gov/pubmed/34745958 http://dx.doi.org/10.3389/fonc.2021.737497

Ejemplares similares

Dose–Response Between Serum Prealbumin and All-Cause Mortality After Hepatectomy in Patients With Hepatocellular Carcinoma
por: Huo, Rong-Rui, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy
por: Deng, Zhu-Jian, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research
por: Wu, Shilun, et al.
Publicado: (2022)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
por: Feng, Jin-Kai, et al.
Publicado: (2022)

Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma
por: Bao, Yingying, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
por: Liu, Lei, et al.
Publicado: (2022)

Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
por: Teng, Yu-Xian, et al.
Publicado: (2022)

Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
por: Zhang, Qi, et al.
Publicado: (2020)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
por: Dai, Xinlun, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion
por: Su, Ting-Shi, et al.
Publicado: (2020)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
por: Li, Xiaowei, et al.
Publicado: (2022)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
por: Chen, Kang, et al.
Publicado: (2022)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Identification and Validation of an 6-Metabolism-Related Gene Signature and Its Correlation With Immune Checkpoint in Hepatocellular Carcinoma
por: Ren, He, et al.
Publicado: (2021)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Analysis of prognostic factors affecting immune checkpoint inhibitor therapy in tumor patients exposed to antibiotics
por: Chen, Qian, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis
por: Liu, Hui, et al.
Publicado: (2021)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma
por: Liao, Rui, et al.
Publicado: (2021)

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
por: Chen, Piaohong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mmcd6geaeudokn478mb36ndej6